Literature DB >> 10791633

Acute-phase proteins in patients with systemic sclerosis.

E J Kucharz1, E Grucka-Mamczar, A Mamczar, L Brzezinska-Wcislo.   

Abstract

Acute-phase proteins were determined in serum of 20 women with systemic sclerosis and 10 age-matched healthy controls. All the patients had had symptoms of the disease less than five years. An increase in only a few proteins (haptoglobin, alpha1-acid glycoprotein, complement component C3 and alpha2-macroglobulin) was found. The results indicate for the impaired acute phase response in patients with systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791633     DOI: 10.1007/s100670050039

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 2.  Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Authors:  John Varga; Boris Pasche
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

3.  High acute phase protein levels correlate with pulmonary and skin involvement in patients with diffuse systemic sclerosis.

Authors:  Anna Lis-Święty; Małgorzata Widuchowska; Ligia Brzezińska-Wcisło; Eugeniusz Kucharz
Journal:  J Int Med Res       Date:  2018-03-07       Impact factor: 1.671

Review 4.  Ocular manifestations in patients with systemic sclerosis.

Authors:  Małgorzata Kozikowska; Wojciech Luboń; Eugeniusz J Kucharz; Ewa Mrukwa-Kominek
Journal:  Reumatologia       Date:  2020-12-23

5.  Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors.

Authors:  Martha E Hettema; Dan Zhang; Karina de Leeuw; Ymkje Stienstra; Andries J Smit; Cees G M Kallenberg; Hendrika Bootsma
Journal:  Arthritis Res Ther       Date:  2008-04-25       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.